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Abstract
Although insulin resistance in skeletal muscle is well-characterized, the role of circulating whole blood in the
metabolic syndrome phenotype is not well understood. We set out to test the hypothesis that genes involved in
inflammation, insulin signaling and mitochondrial function would be altered in expression in the whole blood of
individuals with metabolic syndrome. We further wanted to examine whether similar relationships that we have found
previously in skeletal muscle exist in peripheral whole blood cells. All subjects (n=184) were Latino descent from the
Arizona Insulin Resistance registry. Subjects were classified based on the metabolic syndrome phenotype according
to the National Cholesterol Education Program’s Adult Treatment Panel III. Of the 184 Latino subjects in the study,
74 were classified with the metabolic syndrome and 110 were without. Whole blood gene expression profiling was
performed using the Agilent 4x44K Whole Human Genome Microarray. Whole blood microarray analysis identified
1,432 probes that were altered in expression ≥1.2 fold and P<0.05 after Benjamini-Hochberg in the metabolic
syndrome subjects. KEGG pathway analysis revealed significant enrichment for pathways including ribosome,
oxidative phosphorylation and MAPK signaling (all Benjamini-Hochberg P<0.05). Whole blood mRNA expression
changes observed in the microarray data were confirmed by quantitative RT-PCR. Transcription factor binding motif
enrichment analysis revealed E2F1, ELK1, NF-kappaB, STAT1 and STAT3 significantly enriched after Bonferroni
correction (all P<0.05). The results of the present study demonstrate that whole blood is a useful tissue for studying
the metabolic syndrome and its underlying insulin resistance although the relationship between blood and skeletal
muscle differs.
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Introduction
The metabolic syndrome is a complex pathological state that
is associated with obesity, hypertension, atherosclerotic
cardiovascular disease, and type 2 diabetes [1]. An underlying
feature that is present across these common diseases is insulin
resistance, which is defined as a decreased ability of insulin to
perform its biological functions. Moreover, the pathophysiology
of the metabolic syndrome and its associated diseases are
attributable to a low grade inflammation [2]. Over the past three
decades, the prevalence of the metabolic syndrome has
increased, largely due to the increased prevalence observed
for obesity and type 2 diabetes [3-6]. The metabolic syndrome
(also referred to as insulin resistance syndrome and syndrome
X), can be defined in various ways [7], with the essential
components including obesity, dyslipidemia, hypertension, and
glucose intolerance.
To date, the majority of our work has focused on skeletal
muscle insulin resistance, where we have used global
proteomics and transcriptomic approaches to demonstrate the
relationship between inflammation, extracellular remodeling,
cytoskeletal interactions, and mitochondrial function [2].
Moreover, many cellular, molecular and biochemical defects
have been shown to contribute to the pathophysiology of
insulin resistance including impaired insulin signaling, reduced
insulin-stimulated glucose uptake, lower insulin-stimulated
activities of enzymes such as hexokinase and glycogen
synthase, increased toxic lipid metabolites and impaired
mitochondrial function [8-16]. Studying skeletal muscle in
relation to insulin resistance and its associated diseases such
as the metabolic syndrome is particularly important, as under
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normal physiological conditions this tissue is the major site of
insulin-stimulated glucose disposal [17]. To date, the role of
peripheral whole blood in the metabolic syndrome and the
underlying insulin resistance is less understood. As such, one
of the main objectives of this study was to determine whether
relationships that we have found in the skeletal muscle similarly
exist in the peripheral whole blood cells, so that we could
eventually use whole blood as a surrogate tissue for studying
the metabolic syndrome.
By using global transcriptomic approaches, we set out to test
the hypothesis that there would be changes in the expression
of genes involved in inflammation, insulin signaling and
mitochondrial function in the whole blood of the subjects
classified with the metabolic syndrome. Conducting this study
using global gene expression profiling allowed us to test these
hypotheses and at the same time identify novel targets of
metabolic syndrome and its underlying insulin resistance in
whole blood, which could allow for development of new
strategies for diagnosis as well as the identification of novel
treatment targets.
Methods
Subjects
All subjects were Latino descent and were participants of a
community-based diabetes registry. Subjects reported to the
Clinical Research Unit at Arizona State University following an
overnight fast. Metabolic, anthropometric, demographic, and
medical history information were obtained on all subjects. The
study protocol was approved by the Institutional Review Board
of the Arizona State University and all participants provided
informed written consent prior to enrollment.
Classification of metabolic syndrome
Subjects in the present study were classified based on the
metabolic syndrome phenotype according to the National
Cholesterol Education Program’s Adult Treatment Panel III
(NCEP: ATP III). When 3 out of the 5 following characteristics
were present, a diagnosis of metabolic syndrome was
determined: (1) abdominal obesity, given as waist
circumference (> 102 cm men/> 88 cm women), (2) HDL
cholesterol (
< 40 mg/dl men/< 50 mg/dl in women), (3) blood pressure ≥
130/ ≥85 mmHg, (4) fasting glucose ≥ 110 mg/dl and (5)
triglycerides ≥ 150 mg/dl
Oral glucose tolerance test (OGTT)
A 75-g OGTT was performed on each participant following a
10-12 hour overnight fast as previously described [18]. Since
insulin resistance is a unifying hypothesis to describe the
pathophysiology of the metabolic syndrome [19,20], we also
calculated the Matsuda Index of each subject in the study [21].
Whole blood processing for RNA isolation
Blood was collected into PAXgene Blood RNA tubes (BD
Diagnostics, Franklin Lakes, NJ) and stored at -80°C until
processed. Total RNA was isolated using the PAXgene Blood
RNA Kit, as per the manufacturer’s instructions (Qiagen,
Valencia, CA). RNA quality and quantity were determined using
capillary electrophoresis on an Agilent 2100 Bioanalyzer
automated analysis system (Agilent Technologies, Palo Alto,
CA). The RNA absorbance ratio (A260/A280) values and RNA
integrity number (RIN) values were 2.1 ± 0.002 and 8.8 ± 0.03,
respectively.
Microarray processing
Total RNA (500 ng) was amplified and labeled using the
Amino Allyl MessageAmp™ II aRNA Amplification Kit, as per
manufacturer’s instructions (Life Technologies, Carlsbad, CA).
After labeling, antisense RNA (aRNA) was fragmented using
Agilent Gene Expression Hybridization Kit (Agilent
Technologies, Palo Alto, CA), as per instructions. The
fragmented aRNA was hybridized to the 4x44K Whole Human
Genome Microarray (Agilent Technologies, Palo Alto, CA)
using a SureHyb DNA Microarray Hybridization Chamber at
65°C, for 17 hours in a rotating incubator. After hybridization,
slides were washed in Gene Expression wash buffers 1 and 2
as per instructions, and then scanned with an Agilent DNA
microarray scanner (Agilent Technologies, Palo Alto, CA).
Microarray analysis
Feature Extraction Software version 10.5.1.1 (Agilent
Technologies, Palo Alto, CA), was used for analysis of the
array images. The data generated from the image analysis has
been deposited in the ArrayExpress database (www.ebi.ac.uk/
arrayexpress) under accession number E-MEXP-12345. The
data files were imported into GeneSpring version 12 (Agilent
Technologies, Palo Alto, CA). Data were log transformed,
quantile normalized and baseline to median of all samples. The
probes below 20% expression were excluded from the
analysis. A detailed overview of the analysis is shown in Figure
1. Expression values obtained were submitted to a Student’s
unpaired t-test, and P values were adjusted using the
Benjamini-Hochberg multiple testing correction. Significant
probes with a Benjamini-Hochberg P < 0.05 and fold change ≥
1.2 were used for exploratory KEGG pathway analysis using
the database for annotation, visualization and integrated
discovery (DAVID) (http://david.niaid.nih.gov), as previously
described [22]. Moreover, to identify the genes that differed
most robustly, we filtered the probe list further to identify
probes with a Benjamini-Hochberg P < 0.05 and fold change ≥
1.5.
Transcription factor binding motif enrichment analysis
Overrepresentation of transcription factor binding sites
analysis of the differentially expressed genes was performed
using Pscan version 1.2.2 [23]. We selected a region 950 base
pairs upstream and 50 base pairs (-950 to +50 base pair)
downstream of the translational start site for analysis using the
JASPAR [24] and TRANSFAC [25] databases.
Quantitative Real Time PCR (Q-RT-PCR)
Blood expression of various genes was determined using Q-
RT-PCR on the ABI PRISM 7900HT sequence detection
Blood Gene Expression Profiling
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system (Life Technologies, Carlsbad, CA). TaqMan Universal
Fast PCR master mix reagents and the Assay-On-Demand
gene expression primer pair and probes (Life Technologies,
Carlsbad, CA) were added to 20 ng cDNA, which was
synthesized using the ABI High Capacity cDNA Reverse
Transcription Kit, as per manufacturer’s instructions. The
quantity of the gene of interest in each sample was normalized
to that of GAPDH using the comparative (2-∆∆CT) method [26].
Statistical comparisons were performed using Student’s
unpaired t-test.
Substrate and hormone determinations
Plasma glucose concentration was determined by the
glucose oxidase method on an YSI 2300 STAT plus (YSI INC.,
Yellow Springs, OH). Plasma insulin was measured by
enzyme-linked immunosorbent assay (ALPCO Diagnostics,
Salem, NH). A comprehensive metabolic panel, lipid panel and
hemogram panel were performed by a Clinical Laboratory
Improvement Amendments (CLIA) certified commercial
laboratory (Sonora Quest Laboratories, Phoenix, AZ).
Statistical analysis
Independent sample t-tests and χ2 analyses were used to
compare characteristics between the Met Syn-YES group and
Met Syn-NO group. Additional comparison analyses by sex
were performed to examine the differences in phenotypic
characteristics within each Met Syn group. Data that did not
Figure 1.  Flow diagram of the steps used in the analysis
of the microarray data.  
doi: 10.1371/journal.pone.0084002.g001
meet the assumptions for normality were log10 transformed for
significance; however, untransformed data was presented for
ease of interpretation. Analysis of covariance (ANCOVA) was
used to adjust for the effects of age, sex, and the interaction
between age and sex. Data were expressed as the means ±
SE. All data were analyzed using SPSS version 20.0 with a
significant level set at P ≤ 0.05. Microarray statistical analysis is
described above.
Results
Subjects
The characteristics of the subjects that participated in this
study are shown in Table 1. As described above, subjects were
categorized into one of two groups based on the NCEP: ATP III
metabolic syndrome criteria. Of the 184 in the present study,
74 met the criteria for metabolic syndrome (Met Syn-YES) and
110 subjects were classified as not having the metabolic
syndrome (Met Syn-NO). Subjects were matched for sex
across the two groups. The subjects in the Met Syn-NO group
were slightly younger that the Met Syn-Yes group (35 ± 1 and
39 ± 1, respectively). As shown in Table 1, the subjects
categorized in the Met Syn-YES group were obese,
dyslipidemic, glucose intolerant and had elevated blood
pressure. Moreover, the subjects in the Met Syn-YES group
were more insulin resistant than the Met Syn-NO group as
measured by the Matsuda Index. All these differences
remained significant after adjusting for potential covariates
including age, sex, and the interaction between age and sex
(Table 1). Further separation by sex for both Met Syn-YES and
Met Syn-NO, as shown in Table S1, exhibited significant
differences in body fat percentage, HDL, ALT, and 2 hour
plasma insulin concentration.
Analysis of microarray data
Microarray analysis was performed on RNA isolated from
whole blood obtained from the 184 subjects who participated in
this study. Expression values were normalized as described
above then subjected to Student’s unpaired t-test, and P values
were adjusted using the Benjamini-Hochberg multiple testing
correction. Figure 1 provides an overview of the steps used in
the analysis of the microarray data.
A total of 1,432 probes were altered in expression ≥ 1.2 fold
and P < 0.05 after Benjamini-Hochberg correction. The 1,432
probes were submitted to DAVID for exploratory pathway
analysis, and the significant KEGG pathway results are shown
in Table 2. The KEGG pathways that were identified from the
pathway analysis were ribosome, oxidative phosphorylation,
Alzheimer disease, epithelial cell signaling, Huntington disease,
systemic lupus erythematosus, Parkinson disease, endocytosis
and MAPK signaling (Table S2). Figures S1 and S2 show the
fold change data for the individual oxidative phosphorylation
and MAPK signaling genes that were identified from the
pathway analysis.
To identify the genes that differed most robustly, we filtered
the probe list further to identify probes with a Benjamini-
Hochberg P < 0.05 and fold change ≥ 1.5. The filtering analysis
revealed 206 probes that were altered in expression. Of the
Blood Gene Expression Profiling
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206 probes, 67 had unknown gene annotations. The remaining
139 probes represented 90 unique genes (there were multiple
probes associated with the same gene). Of the 90 unique
genes, 20 were lower in expression and the remaining 70 were
higher in expression in the Met Syn-YES group as shown in
Table 3 and 4, respectively. The most robustly expressed gene
that was lower in expression in the Met Syn-YES group was
solute carrier family 45, member 3 (SLC45A3). In addition, the
gene analysis identified multiple ribosomal proteins, oxidative
phosphorylation genes and lactotransferrin (LTF) that were
higher in expression in the Met Syn-YES group (Table 4).
Table 1. Characteristics of subjects classified into one of
two groups based on metabolic syndrome criteria.
 Met Syn-NO Met Syn-YES P Value
P value by
adjustment of
age, sex,
age*sex
Gender 36M/74F 25M/49F NS -
Age (years) 35 ± 1 39 ± 1 <0.01 -
Body Mass Index (kg/m2) 28.3 ± 0.5 35.1 ± 1.1 <0.0001 <0.0001
Body Fat (%) 28.9 ± 0.7 34.5 ± 0.9 <0.0001 <0.0001
Systolic Blood Pressure
(mmHg) 114.7 ± 1.1 128.4 ± 2.4 <0.0001 <0.0001
Diastolic Blood Pressure
(mmHg) 75.3 ± 0.8 81.5 ± 1.2 <0.0001 <0.0001
Hip Circumference (cm) 104.9 ± 1.0 116.2 ± 1.5 <0.0001 <0.0001
Waist Circumference
(cm) 95.1 ± 1.2 109.1 ± 1.7 <0.0001 <0.0001
Triglyceride (mg/dL) 107.7 ± 4.3 204.7 ±12.2 <0.0001 <0.0001
Cholesterol (mg/dL) 166.9 ± 2.9 191.0 ± 4.7 <0.0001 <0.001
High Density Lipoprotein
(mg/dL) 47.8 ± 1.1 37.6 ± 1.0 <0.0001 <0.0001
Low Density Lipoprotein
(mg/dL) 102.4 ± 2.5 117.4 ± 3.9 <0.001 <0.01
Very Low Density
Lipoprotein (mg/dL) 18.0 ± 0.7 30.9 ± 1.5 <0.0001 <0.0001
Alanine
Aminotransferase (IU/L) 22.9 ± 1.3 41.9 ± 3.6 <0.0001 <0.0001
Aspartate
Aminotransferase (IU/L) 22.9 ± 0.9 30.9 ± 2.0 <0.0001 <0.001
Fasting Plasma Glucose
(mg/dL) 92.5 ± 1.8 112.8 ± 4.8 <0.0001 <0.0001
2 Hour Plasma Glucose
(mg/dL) 124.0 ± 4.6 181.4 ± 9.4 <0.0001 <0.0001
Hemoglobin AIc (%) 5.6 ± 0.1 6.2 ± 0.1 <0.0001 <0.0001
Fasting Plasma Insulin
(uIU/mL) 7.3 ± 0.5 12.8 ± 1.3 <0.0001 <0.0001
2 Hour Plasma Insulin
(uIU/mL) 59.6 ± 5.4
104.9 ±
12.8 <0.0001 <0.0001
Matsuda Index 7.3 ± 0.7 3.5 ± 0.4 <0.0001 <0.0001
Data are mean ± SE
doi: 10.1371/journal.pone.0084002.t001
Transcription factor binding motif enrichment analysis
To further understand the genes altered in expression in this
study, we analyzed the promoter regions (-950 to +50 base
pair) of the unique genes that differed most robustly (n=90) for
enrichment in transcription factor response element binding
motifs using PScan. We used response element profiles
available in both the JASPAR and TRANSFAC databases and
searched for enrichment that was significant using both
databases. Table 5 shows the results of the transcription factor
response element binding motifs.
Quantitative RT-PCR analysis to confirm microarray
data
To validate the microarray data, we quantitated the changes
in mRNA levels of 11 genes (9 of which higher and 2 of which
lower in expression using microarray analysis) using RT-PCR
in 30 subjects; 15 subjects from Met Syn-YES, and 15 subjects
from Met Syn-NO. Subjects in each group were randomly
selected from the 184 individuals that participated in the
microarray study. Genes for confirmation by RT-PCR were
randomly selected from the differentially expressed list. Table 6
shows the results of the RT-PCR analysis. The changes in
gene expression determined by Q-RT-PCR were concordant
with changes in gene expression determined by microarray
analysis.
Discussion
The present study was undertaken to decipher the role of
peripheral whole blood in relation to the metabolic syndrome
phenotype. We set out to test the hypothesis that genes
involved in inflammation, insulin signaling and mitochondrial
function would be altered in expression in the whole blood of
individuals with metabolic syndrome. We further wanted to
examine whether similar relationships that we have found
previously in skeletal muscle exist in peripheral whole blood
Table 2. Results of the significant KEGG pathway analysis
performed in DAVID on the 1,432 probes that were altered
in expression ≥ 1.2 fold and P < 0.05 after Benjamini-
Hochberg correction.
KEGG Pathway
Probe
Count Up Regulated
Down
Regulated Significance
Ribosome 119 119 0 <0.0001
Oxidative
Phosphorylation 32 28 4 <0.0001
Alzheimer Disease 31 22 9 <0.01
Epithelial Cell Signaling 15 1 14 <0.01
Huntington Disease 29 23 6 <0.05
Systemic Lupus
Erythematosus 31 1 30 <0.05
Parkinson Disease 23 22 1 <0.05
Endocytosis 28 0 28 ≤0.05
MAPK Signaling 36 0 36 0.057
doi: 10.1371/journal.pone.0084002.t002
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cells. It has been shown elsewhere that over 80% of the genes
expressed in nine different human tissue types overlapped with
the peripheral blood transcriptome [27]. Therefore, the
peripheral blood cells express a large proportion of the genes
in the human genome, suggesting that whole blood may be
useful as a surrogate for studying metabolic syndrome and
related conditions such as insulin resistance, diabetes and
obesity.
We performed global transcriptomic analyses of peripheral
whole blood as it is an easy tissue to obtain and it is therefore
non-invasive. We performed genome-wide gene expression
profiling on RNA obtained directly from whole blood collected in
PAXgene tubes rather than use peripheral blood mononuclear
cells (PBMCs). The disadvantage of using the PAXgene tubes
Table 3. Results of GeneSpring analysis revealed 206
probes that were altered in expression ≥ 1.5 fold and P <
0.05 (Benjamini corrected).
Probe Name Gene Description Gene Symbol
Fold
Change
A_24_P208345 solute carrier family 45, member 3 SLC45A3 -2
A_23_P10559 apoptosis-associated tyrosinekinase AATK -1.6
A_23_P501933 calcium channel, voltage-dependent, gamma subunit 6 CACNG6 -1.6
A_23_P166297 ATP-binding cassette, sub-family G,member 1 ABCG1 -1.5
A_23_P127948 adrenomedullin ADM -1.5
A_23_P417383 aspartic peptidase, retroviral-like 1 ASPRV1 -1.5
A_23_P4662 B-cell CLL/lymphoma 3 BCL3 -1.5
A_23_P359052 biorientation of chromosomes in celldivision 1-like BOD1L -1.5
A_23_P210811 CD93 molecule CD93 -1.5
A_23_P119562 complement factor D (adipsin) CFD -1.5
A_23_P7144
chemokine (C-X-C motif) ligand 1
(melanoma growth stimulating
activity, alpha)
CXCL1 -1.5
A_23_P257924 v-ets erythroblastosis virus E26oncogene homolog 2 ETS2 -1.5
A_23_P99661 hypothetical protein FLJ10357 FLJ10357 -1.5
A_23_P67847
UDP-N-acetyl-alpha-D-
galactosamine:polypeptide N-
acetylgalactosaminyltransferase 14
GALNT14 -1.5
A_23_P110022 GATA binding protein 2 GATA2 -1.5
A_32_P217750 interleukin 3 receptor, alpha (lowaffinity) IL3RA -1.5
A_24_P282060 hypothetical proteinLOC100128439 LOC100128439 -1.5
A_23_P114466 transducin (beta)-like 1Y-linked TBL 1Y -1.5
A_23_P145965 tyrosylprotein sulfotransferase 1 TPST1 -1.5
A_23_P55606 zinc finger protein 516 ZNF516 -1.5
Of the 206 probes, 67 had unknown gene annotations and the remaining 139
probes represented 90 unique genes (multiple probes associated with the same
gene). Of the 90 unique genes, 20 were lower in expression in the Met Syn-YES
group.
doi: 10.1371/journal.pone.0084002.t003
Table 4. Results of GeneSpring analysis revealed 206
probes that were altered in expression ≥ 1.5 fold and P <
0.05 (Benjamini corrected).
Probe Name Gene Description Gene Symbol FoldChange
A_32_P220127 ribosomal protein L34 RPL34 +2.7
A_24_P6975 ribosomal protein L34 pseudogene34 RPL34P34 +2.2
A_32_P31182 ribosomal protein L7 pseudogene26 RPL7 +2.2
A_32_P196483 ribosomal protein S3A pseudogene5 RPS3A +2.2
A_24_P152753 ribosomal protein L31 pseudogene18 RPL31P18 +2.1
A_24_P41551 ribosomal protein L31 pseudogene39 RPL31P39 +2.1
A_23_P159650 cytochrome c oxidase subunit VIIb COX7B +2.0
A_23_P128192 prefoldin subunit 5 PFDN5 +2.0
A_24_P366546 ribosomal protein L31 pseudogene10 RPL31P10 +2.0
A_32_P145153 ribosomal protein L31 pseudogene49 RPL31 +2.0
A_24_P76358 ribosomal protein S3a pseudogene36 RPS3AP36 +2.0
A_23_P166848 lactotransferrin LTF +1.9
A_23_P34018 ribosomal protein L39 pseudogene10 RPL39 +1.9
A_24_P232856 ribosomal protein L9 RPL9 +1.9
A_24_P186944 ribosomal protein L9 pseudogene18 RPL9P18 +1.9
A_24_P144666 ribosomal protein S3a pseudogene10 RPS3AP10 +1.9
A_32_P21384 ribosomal protein L17 pseudogene22 RPL17 +1.8
A_24_P366165 ribosomal protein L26 pseudogene12 RPL26P12 +1.8
A_24_P135551 ribosomal protein L26 pseudogene13 RPL26P13 +1.8
A_24_P212864 ribosomal protein L26 pseudogene21 RPL26P21 +1.8
A_24_P161914 ribosomal protein L7 pseudogene13 RPL7P13 +1.8
A_24_P169378 ribosomal protein S7 RPS7 +1.8
A_24_P15765 ribosomal protein S7 pseudogene5 RPS7P5 +1.8
A_24_P127181 ribosomal protein S7 pseudogene8 RPS7P8 +1.8
A_23_P168916 carbonic anhydrase I CA1 +1.7
A_23_P132863 LSM3 homolog, U6 small nuclearRNA associated (S. cerevisiae) LSM3 +1.7
A_32_P30710 ribosomal protein L23 pseudogene6 RPL23 +1.7
A_32_P22539 ribosomal protein L26 pseudogene32 RPL26P32 +1.7
A_23_P33045 ribosomal protein L26 pseudogene33 RPL26 +1.7
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Table 4 (continued).
A_24_P106306 ribosomal protein L26-like 1 RPL26L1 +1.7
A_32_P136319 ribosomal protein L36apseudogene 51 RPL36A +1.7
A_24_P153324 ribosomal protein L7 pseudogene44 RPL7P44 +1.7
A_24_P349636 ribosomal protein L7 pseudogene48 RPL7P48 +1.7
A_24_P84808 ribosomal protein L7 pseudogene50 RPL7P50 +1.7
A_24_P221366 ribosomal protein S15apseudogene 17 RPS15A +1.7
A_24_P375849 ribosomal protein S17 pseudogene2 RPS17P2 +1.7
A_23_P1206 ribosomal protein S24 RPS24 +1.7
A_32_P4532 ribosomal protein S3a pseudogene20 RPS3AP20 +1.7
A_23_P59921 SUB1 homolog (S. cerevisiae) SUB1 +1.7
A_32_P98348 zinc finger protein 525 ZNF525 +1.7
A_23_P170233 cystatin A (stefin A) CSTA +1.6
A_23_P8900 cytochrome c oxidase subunit VIc COX6C +1.6
A_23_P110811 cytochrome c oxidase subunit VIIc COX7C +1.6
A_32_P336445 histidine triad nucleotide bindingprotein 1 HINT1 +1.6
A_32_P25253 iron-sulfur cluster assembly 1homolog (S. cerevisiae) ISCA1 +1.6
A_23_P145777
NADH dehydrogenase
(ubiquinone) 1 alpha subcomplex,
4, 9kDa
NDUFA4 +1.6
A_23_P65466 RAB2B, member RAS oncogenefamily RAB2B +1.6
A_23_P65768 ribosomal L24 domain containing 1 RSL24D1 +1.6
A_32_P203154 ribosomal protein L21 pseudogene134 RPL21 +1.6
A_23_P143958 ribosomal protein L22-like 1 RPL22L1 +1.6
A_23_P128067 ribosomal protein L41 RPL41 +1.6
A_23_P258108 ribosomal protein L9 pseudogene16 RPL9P16 +1.6
A_23_P14734 ribosomal protein S27-like RPS27L +1.6
A_23_P70843 2,3-bisphosphoglycerate mutase BPGM +1.5
A_24_P188116 ankyrin repeat domain 2 (stretchresponsive muscle) ANKRD2 +1.5
A_23_P255827 apoptosis inhibitor FKSG2 +1.5
A_32_P123771
ATP synthase, H+ transporting,
mitochondrial F1 complex, epsilon
subunit
ATP5E +1.5
A_23_P138985 CD3d molecule, delta (CD3-TCRcomplex) CD3D +1.5
A_23_P205281 chromosome 14 open readingframe 2 C14orf2 +1.5
A_23_P212854 glycophorin E; glycophorin B (MNSblood group) GYPB +1.5
A_23_P413796 HAUS augmin-like complex,subunit 1 HAUS1 +1.5
A_23_P87346 hemoglobin, delta HBD +1.5
and studying whole blood is that the results generated from this
gene expression profiling study represent the contribution of
RNA from all blood cell types. Whole blood is a complex tissue
comprised of many cell types including neutrophils,
eosinophils, basophils, B cells, T cells, and monocytes. As
such, when using the PAXgene tube approach we cannot
definitely state which cell type is contributing the mRNA
expression signal. However, the goal for this study was to
develop a transcriptome for studying metabolic syndrome in
whole blood, and we chose the PAXgene tubes to minimize
RNA degradation, to minimize handling and potential activation
of blood cells, and to minimize loss of sample in purification of
specific sub populations of leukocytes, all of which could affect
gene expression levels.
In the present study, fold changes ranged from -2 to +2.7,
which were much lower than our previous studies in skeletal
muscle where observed changes range from -3 to +8 [22,28].
Moreover, it has been observed elsewhere that the gene
expression levels from PAXgene RNA are much lower when
compared to studies using PBMCs [29,30]. Ghosh et al.,
addressed this issue and suggested that the lower fold change
Table 4 (continued).
A_24_P203827 histidine triad nucleotide bindingprotein 1 pseudogene HINT1P1 +1.5
A_23_P502425 mitochondrial ribosomal proteinL47 MRPL47 +1.5
A_24_P168416 peroxiredoxin 2 PRDX2 +1.5
A_32_P34201 ribosomal protein L6 pseudogene13 RPL6P13 +1.5
A_24_P575336 ribosomal protein L6 pseudogene 3 RPL6P3 +1.5
A_23_P76961 ribosomal protein S29 pseudogene11 RPS29 +1.5
A_23_P434809 S100 calcium binding protein A8 S100A8 +1.5
A_23_P93844 translocase of outer mitochondrialmembrane 7 homolog (yeast) TOMM7 +1.5
Of the 206 probes, 67 had unknown gene annotations and the remaining 139
probes represented 90 unique genes (multiple probes associated with the same
gene). Of the 90 unique genes, 70 were higher in expression in the Met Syn-YES
group.
doi: 10.1371/journal.pone.0084002.t004
Table 5. Results of the transcription factor binding motif
enrichment analysis.
Transcription Factor P Value*
E2F1 <0.01
ELK1 <0.05
NF-kappaB <0.01
STAT1 <0.001
STAT3 <0.01
* Bonferroni P values refer to enrichment of transcription factors relative to random
selection of 5’UTRs in genome (PScan)
doi: 10.1371/journal.pone.0084002.t005
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ranges in PAXgene analyses is attributable to the high
abundance of globin in the whole blood [30]. Although 70% of
whole blood mRNA is represented by globin, we were able to
validate the gene expression changes captured in the
microarray with quantitative RT-PCR. This indicates that the
changes observed in the present study were present,
suggesting that the genes and pathways are biologically
relevant and could be used for development of new strategies
for diagnosis as well as the identification of novel treatment
targets.
In this study, each individual was classified based on
metabolic syndrome criteria. Metabolic syndrome was used to
classify our sample population due to its known concordance
with type 2 diabetes, obesity, hypertension, and atherosclerotic
cardiovascular disease [1]. For this study, the relationship
between insulin resistance and the NCEP: ATP III phenotypic
criteria for metabolic syndrome were reinforced by
measurements of Matsuda Index [21]. We have previously
used the Matsuda index, which is considered a surrogate
measure of whole body insulin sensitivity obtained from the
OGTT [18,21]. However, in the present study, the Matsuda
index was not solely used to determine groupings since a clear
cut-off point for classification of insulin resistance versus insulin
sensitivity in Hispanic populations has not yet been defined. In
the present study, the metabolic syndrome criteria provides
groupings that are reinforced by multiple variables, one of
which being insulin sensitivity. Subjects classified with
metabolic syndrome were more insulin resistant, which was
fully anticipated since insulin resistance is thought to be the
core defect underlying this condition [19,20]. It could be argued
that the significant differences for the metabolic characteristics
between the two groups could be due to age since the
individuals without metabolic syndrome were slightly younger in
age.
Table 6. Results of the mRNA expression determined by Q-
RT-PCR (with corresponding microarray results shown).
Gene Q-RT-PCR Fold Change Microarray Fold Change
ATP5E 1.2 1.5
CACNG6 -1.5* -1.6
COX7B 1.8* 2.0
COX7C 1.8* 1.6
CSTA 1.4* 1.6a
LTF 2.3* 1.9
NDUFA4 1.2* 1.6a
PFDN5 1.5* 2.0a
RPL34 1.6* 2.7a
RPS3A 1.3* 2.2a
SLC45A3 -2.6* -2
a More than one probe set was significantly altered for this gene on the microarray.
The probe set with the greatest fold change in the microarray analysis is
represented here. Significance for the genes selected for Q-RT-PCR was
assessed looking at each dataset separately and using Student’s unpaired t-test.
*P < 0.05 vs. control GAPDH RNA (used for Q-RT-PCR analysis).
doi: 10.1371/journal.pone.0084002.t006
Table S1 provided sex associated differences within the Met
Syn-NO and Met Syn-YES groupings. The body fat percentage
was significantly higher in women than men, and it has been
shown that women tend to have larger proportion of body fat
mass, and a higher yield of fat storage than men [31]. Fat
metabolism involves the transportation of free fatty acids for
storage. An important molecule which assists with this process
is HDL. The levels of HDL in our subjects were significantly
higher in women than men. The observed sex difference could
be due to the premenopausal state in women, where there is
typically lower total cholesterol and triglycerides, and higher
HDL levels than men because of sex hormone regulation
differences in fat metabolism [32]. This possible explanation
could be applied to the current study based on the average
female ages being below the typical age of menopause, and
the same trend as described for the triglycerides, cholesterol,
and HDL (as shown in Table S1).
Another significant sex difference was found in the 2 hour
plasma insulin concentrations, where the women were found to
have higher levels than men. These results could be reflective
of the study conducted by Magkos et al., which considered the
effects of insulin and the suppression of endogenous glucose
production between men and women [33]. When their subjects
were infused with insulin to raise insulin concentrations to
15-20 mU/L, women had a prolonged suppression of
endogenous glucose production than men [33]. This could infer
that the proposed concentration of infused insulin is sustained
longer in women. Another point of interest was the significantly
higher levels of ALT in men than in women. A study performed
elsewhere demonstrated that ALT (≥ 40 U/L) could be used as
a predictor for coronary heart disease (CHD) in men, but not
women [34]. The sex differences in ALT may also be due to the
level of work performed by the liver in men (hepatic glucose
production was not as easily suppressed) as opposed to
women, as suggested in the aforementioned study [33]. Men
were also found to present signs of CHD about ten years
before women, so the average ages of the male and female
subjects in our current study may add to the discrepancy [34].
In the present study, there was a higher expression of
oxidative phosphorylation genes observed in the individuals
classified with the metabolic syndrome phenotype. The higher
expression in oxidative phosphorylation genes in whole blood
is contradictory to the observed findings in skeletal muscle. We
[15] and others [16] have demonstrated that nuclear encoded
mitochondrial genes encoding proteins involved in electron
transport and oxidative phosphorylation were decreased in
insulin resistant muscle, and many of these changes could be
attributed to lower peroxisome proliferator-activated receptor
alpha (PPAR alpha) coactivator-1 alpha (PGC-1 alpha) gene
expression [15]. We also showed that experimental insulin
resistance produced by a lipid infusion in healthy volunteers
decreases the mRNA expression of PGC-1 alpha and other
mitochondrial and oxidative phosphorylation genes [28]. The
discrepancies in the expression of genes involved in oxidative
phosphorylation may be attributable to differences in tissue
types and the role that each plays in the disease. A similar
study using PAXgene tubes demonstrated an increased
expression in oxidative phosphorylation genes in an obese
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Northern European White cohort; specifically cytochrome c
oxidase subunits C6, B7, C7, and NADH dehydrogenase 1
alpha sub-complex 4 showed significant enrichment in both
studies [30]. The increase in oxidative phosphorylation genes
in whole blood may be caused by a response to increased
energy demands in the metabolic syndrome individuals [30], or
may be explained by an inflammation-induced increase in
reactive oxygen species (ROS) generation. Although ROS was
not measured in the present study, we know from other studies
that in insulin resistant individuals the glucose levels in the
bloodstream are elevated, which could increase the metabolic
substrate input of the mitochondria leading to stress on the
electron transport chain and causing an overproduction of ROS
[35]. When the blood contains high amounts of ROS, a
condition called oxidative stress is created. Previous studies
have shown that oxidative stress plays key roles in diabetes,
cardiovascular disease, and neurological disorders [36].
Although we observed similar findings to Ghosh et al., there
were differences in our study design; our subjects were Latin
descent, categorized based on metabolic syndrome criteria and
we had much higher numbers of individuals entering into the
analysis.
The ribosome genes and pathway had a strong, distinct
association with metabolic syndrome. Interestingly, all of the
genes within the pathway showed an increase in expression.
These results suggest that in the peripheral blood of individuals
with the metabolic syndrome there is an increase in the cellular
content of ribosomes augmenting the capacity for protein
synthesis. The increase in ribosomes suggests that there is
possibly an increase in protein synthesis to account for the
increased energy demands observed in individuals with the
metabolic syndrome; the significantly enriched genes possibly
accounting for this phenomena (also found in Ghosh et al.)
being ribosomal protein L7, S7, S24, and S31 [30]. Another
study had shown a direct correlation between energy demands
and ribosomal RNA synthesis through AMP-activated protein
kinase in mammalian cells [37]. Their findings suggest that
ribosomal RNA synthesis will increase when mitogenic
conditions are optimal; for example, an overabundance of
available nutrients. Therefore, it is possible that the
physiological conditions of our sample population could provide
optimal conditions for ribosomal RNA synthesis from the
elevated levels of glucose.
An increase in ribosomal genes could also be linked to
inflammation. Insulin resistance causes an environment in
which deoxyhypusine synthase (DHS) promotes cytokine-
induced inflammation in β-cells, as well as catalyzes the
conversion of lysine to hypusine that is unique to the
translational elongation factor eIF5A found in the endoplasmic
reticulum (ER) [38]. Therefore, when β-cell dysfunction occurs
due to inflammatory stress, DHS also causes ER stress by
eIF5A increased production of proteins [38]. A recent study
performed by Yamaoka et al. on blood gene expression in
Japanese cohorts separated by metabolic syndrome
classifications also identified chronic low-grade inflammation
related to ROS production; however, their study focused on
data related to adipose tissue as opposed to skeletal muscle
[39]. An interesting similarity between our studies is the
increased expression of S100A8 related to metabolic syndrome
explained by Yamaoka et al., which stated a correlation
between the expression and ROS generation promoted by
calprotectin (a S100A8/A9 complex) [40].
Our study demonstrated alterations in the MAPK signaling
pathway genes with metabolic syndrome. Interestingly, all of
the genes identified in the analysis were lower in expression in
the metabolic syndrome individuals. We hypothesized that
there would be alterations in genes involved in insulin
signaling; however we expected to observe increased
expression. Several studies have indicated that insulin
resistance is connected to an escalation in activity from JNK
and p38 in MAPK signaling pathway [41]. Since this was not
the case in our study, the discrepancies may be explained by
differences in blood tissue compared with skeletal muscle. The
differences seen in blood may be related to the relationship
between insulin resistance and endothelial dysfunction.
Normally, insulin induces phosphatidylinositol 3-kinase
dependent signaling (PI3K) to produce nitric oxide (NO) which
increases blood flow in the vascular endothelium, and
ultimately increases glucose uptake in skeletal muscle [42].
This process is accompanied by the MAPK-dependent insulin-
signaling pathway that produces endothelin-1, which
determines vascular responses to insulin [42]. Endothelial
dysfunction is usually viewed as an imbalance that occurs in an
insulin resistant state, where PI3K signaling is impaired and
MAPK signaling is heightened [42]. The results from our study
may indicate that blood is more sensitive to the effects
occurring to PI3K in the vascular endothelium in relation to
MAPK signaling, but not the actual enhanced effects of MAPK.
In this study, the endocytosis pathway was lower in
expression in the individuals classified with metabolic
syndrome. These results are reinforced from a recent study on
the role of autophagy in metabolism. Autophagy is a
homeostatic mechanism that is typically known for transporting
items such as damaged organelles or misfolded proteins to the
lysosome to be degraded [43]. This process has also been
viewed as a generator for cellular energy from protein
degradation into amino acids and its role in the releasing free
fatty acids to be used for beta-oxidation [43]. This ability to
provide energy is increased under conditions of starvation
coupled by internal stimuli such as oxidative stress, protein
aggregation, and damaged organelles [44]. However, in our
metabolic syndrome group, there is an excess supply of
nutrients. Autophagy activity is decreased in environments with
elevated glucose, because glucagon causes the up regulation
in autophagy [43]. These findings provide some evidence with
the decreased expression seen in endocytosis for our sample
population.
From our analysis a cluster of neurological pathways were
found to be significant in metabolic syndrome, which included
Alzheimer’s disease, Huntington’s disease, and Parkinson’s
disease. The relevance of this finding is due to the growing
efforts to study the late effects of metabolic syndrome type
environments on the neurological system; mainly efforts to
mark Alzheimer’s disease as type 3 diabetes [45]. The
connection between metabolic syndrome and the nervous
system is primarily due to insulin, which in the central nervous
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system plays a role in controlling neuronal function (memory
and cognitive functioning), neurotransmitter release, and
synaptic plasticity [45]. Insulin receptors are located in both
neurons and glia of the brain, and are specifically prevalent in
regions such as, the hypothalamus, cerebellum, olfactory bulb,
hippocampus and cerebral cortex [46]. In conditions where
prolonged elevation of glucose causes hyperinsulinemia (as
associated with insulin resistance) in the bloodstream, a
reduction of insulin crossing the blood brain barrier can occur
[46]. Such an environment is thought to cause a shift to
peripheral insulin use which can lead to downstream affects in
memory, learning, and neuronal survival [45].
The systemic lupus erythematosus (SLE) pathway was found
to be altered in our metabolic syndrome subjects. SLE has
been described as a chronic inflammatory disease
characterized by abnormal T and B cell function and production
of antinuclear antibodies [47]. Inflammation is prominent in
SLE, as well as insulin resistance and metabolic syndrome [2].
In the present study, an inflammatory marker that was
increased in expression in the metabolic syndrome individuals
was lactotransferrin, which has been shown to be increased in
concentration during most inflammatory reactions [48].
Interestingly, in patients with SLE there is a four times greater
chance of having the metabolic syndrome than without SLE
[49]. Some of the genes affected in the oxidative
phosphorylation pathway were also present in the SLE
pathway. This could be attributed to the relationship of SLE
with mitochondria. Individuals with SLE have been known to
exhibit spontaneous apoptosis and defective activation-induced
cell death of the T cells [47]. Since cell proliferation and
apoptosis are energy-dependent processes, a disruption in the
functionality of the mitochondria and alterations in ROS is
suggested [47]. The most predominant finding in the SLE
pathway analysis was the reduced expression in histone
related genes in those individuals with metabolic syndrome.
This decrease could be explained by a recent study that
showed that the majority of individuals with SLE create anti-
histone antibodies specifically directed towards histones within
neutrophil extracellular traps (NETs) [49]. Neutrophils are one
of the many cells found within whole blood, and if our
population sample has similar physiology to SLE individuals it
is possible that our results are showing that specific type of
autoreactivity.
Collectively, the global transcriptomic analyses on metabolic
syndrome in our Latino population provided data that whole
blood may be a useful surrogate for studying particular
pathways. Based on our findings, pathways involved in
ribosomes, Alzheimer’s disease, Huntington’s disease,
Parkinson’s disease, systemic lupus erythematosus, and
endocytosis may logistically continue studies using whole blood
in relation to outcomes of metabolic syndrome. However, the
pathways specifically linked to mitochondrial genes, such as
oxidative phosphorylation and MAPK signaling have shown
reversed outcomes in whole blood than seen in skeletal muscle
for reasons that need further investigation.
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